Close

Cellerant gets additional funding from BARDA

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Cellerant Therapeutics has received additional funding of approximately $16.7m from Biomedical Advanced Research and Development Authority to advance CLT-008 development as a treatment for acute radiation syndrome .

The additional funding is expected to support Cellerant’s CLT-008 development strategy to expand its current clinical trials, process development and manufacturing activities and to fund additional nonclinical studies required for approval in ARS.

The current funding is a part of an existing contract valued at up to $153.2m previously awarded on 1 September 2010.

As per the revised deal, BARDA will grant up to $80m, in the two year base period of performance and up to an additional $89.9m in three option years, bringing the total value of the contract to $169.9m.

Cellerant president and CEO Ram Mandalam said they continue to make progress and the supplemental funding provides additional resources to advance CLT-008 closer to approval for therapeutic use.

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back